stockrow
Monday 2 November 2026
Export TWST’s income statement to Excel — free account
Twist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
129.86
22.92
−15.00%
Follow TWST
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.47 | 4.95 | 7.16 | 14.87 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(142.46) | (78.08) | (166.98) | 5,757.87 | |
P/B ratio |
3.56 | 4.25 | 6.44 | 14.40 | |
Price to Tangible BV |
4.46 | 5.37 | 8.15 | 18.30 | |
EV/Sales |
3.90 | 4.48 | 6.78 | 14.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(30.80) | (34.42) | (49.96) | (118.14) | |
EV/FCF |
(19.40) | (20.25) | (29.22) | (65.57) | |
Quick Ratio |
3.17 | 3.08 | 1.97 | 1.93 | |
Current Ratio |
3.64 | 3.78 | 2.70 | 2.67 | |
Net Debt/EBITDA |
9.09 | 6.85 | 3.97 | 5.15 | |
Debt/Assets |
2.34% | 2.35% | 2.22% | 2.23% | |
Debt/Equity |
0.03 | 0.03 | 0.03 | 0.03 | |
Asset Turnover |
0.60 | 0.63 | 0.64 | 0.66 | |
Operating CF/Net income |
0.44 | 0.81 | 0.40 | (0.03) | |
Capex/Depreciation |
(2.49) | (1.61) | (1.25) | (1.44) | |
Research and Development Expense of Revenue |
17.18% | 16.52% | 17.79% | 15.23% | |
Selling, General and Administrative Expense of Revenue |
64.40% | 67.25% | 68.72% | 68.18% | |
Intangible Assets out of Total Assets |
0.15 | 0.15 | 0.14 | 0.14 | |
Share Based Compensation of Revenue |
16.24% | 12.80% | 17.10% | 15.35% | |
Graham Net Nets |
0.10 | 0.06 | 0.03 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.62%) | (4.00%) | (2.78%) | (2.16%) | |
Free Cash Flow Yield |
(4.49%) | (4.48%) | (3.24%) | (1.49%) | |
Revenue per Share |
1.66 | 1.70 | 1.79 | 1.90 | |
Operating CF per Share |
(0.20) | (0.41) | (0.28) | 0.02 | |
Capex per Share |
(0.25) | (0.16) | (0.13) | (0.16) | |
Free Cash Flow per Share |
(0.45) | (0.57) | (0.41) | (0.14) | |
Cash per Share |
3.89 | 3.24 | 2.78 | 2.67 | |
Shareholders Equity per Share |
7.91 | 7.47 | 7.38 | 7.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.91 | 7.47 | 7.38 | 7.14 | |
Free Cash Flow |
(26.74) | (34.79) | (25.55) | (8.65) | |
Working Capital |
241.56 | 223.44 | 203.46 | 201.04 | |
Capital Expenditures |
(14.93) | (9.97) | (7.99) | (9.76) | |
Net Current Asset Value |
164.06 | 121.89 | 102.32 | 94.60 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.15 | 0.10 | 0.07 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
45.96 | 44.69 | 57.05 | 57.45 | |
Average Payables |
6.36 | 10.00 | 11.37 | 14.51 | |
Average Inventory |
26.19 | 28.22 | 27.19 | 30.55 | |
Average Assets |
628.09 | 623.33 | 635.91 | 658.02 | |
Average Common Equity |
472.82 | 456.02 | 447.60 | 461.97 |
Columns are period end dates